Compare IDEXX Laboratories, Inc. (IDXX) vs Direxion Daily FTSE China Bull 3x Shares (YINN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Direxion Daily FTSE China Bull 3x Shares — how do they compare? IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B), while Direxion Daily FTSE China Bull 3x Shares trades at $25.27 (market cap $560.32M). The key difference: IDEXX Laboratories, Inc. is far larger — about 72.2× Direxion Daily FTSE China Bull 3x Shares's market cap, and IDEXX Laboratories, Inc. is more actively traded (692,164 versus 1,009,521). Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and Direxion Daily FTSE China Bull 3x Shares for 25 Days on average.
| IDXX | YINN | |
|---|---|---|
Market Cap | $40.43B | $560.32M |
Volume | 692,164 | 1,009,521 |
Sector | Health | Leveraged / Inverse |
52-Week High | $766.68 | $52.69 |
52-Week Low | $504.70 | $21.45 |
Typical Hold Time | 46 Days | 25 Days |
Enterprise Value | $41.32B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $518.00, up 2.24% with strong earnings beats in recent quarters. The stock shows bearish technical signals but maintains robust fundamentals with 25.03% net margins and 74.21% ROE. Recent acquisitions like CoVetAI and product expansions highlight growth initiatives. Analyst consensus remains bullish with a $665 price target, though technical indicators suggest near-term caution.
Outlook remains positive driven by diagnostic innovation and recurring revenue growth, but faces headwinds from FX volatility and weaker U.S. vet visits. The 36.06 P/E ratio reflects premium valuation, requiring sustained execution. Risks include competitive pressures and insider selling, while institutional ownership trends show mixed signals.
YINN is trading at $25.27, up 7.26% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The stock lacks disclosed fundamental ratios such as P/E and P/S, and recent news highlights China's economic policies and energy sector dynamics, which may influence its performance. Support is clustered around $23, with resistance at $24.
The outlook remains cautious due to bearish technicals and limited fundamental visibility. Risks include reliance on Chinese economic conditions and potential regulatory changes. Investment opportunities hinge on improved earnings transparency and positive shifts in market sentiment, but current data suggests a neutral to bearish stance for near-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Direxion Daily FTSE China Bull 3x Shares
YINN is a leveraged ETF that seeks daily investment results, before fees and expenses, of 300% (3x) of the daily performance of the FTSE China 50 Index. It is a tactical instrument designed for sophisticated traders seeking to magnify short-term bullish views on large-cap Chinese equities, primarily those trading on the Hong Kong Stock Exchange.
Read more on YINN →
